Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Oral OTEZLA (Apremilast) Demonstrated Significant Improvement versus Placebo in Trial of Patients with Moderate Plaque Psoriasis Who Were Naïve to Systemic and Biologic Therapy

Encouraging results were reported from UNVEIL, the first trial of patients with moderate plaque psoriasis who were naïve to systemic and biologic therapy.

Read More »

Seattle Genetics to resume trials as FDA lifts clinical hold

Seattle Genetics Inc. said the U.S. Food and Drug Administration lifted a clinical hold on several early-stage studies testing its experimental cancer drug.

Read More »

Latest Dupixent eczema drug tests positive

Sanofi and Regeneron said results from a one-year test of Dupixent aimed at adults with eczema or moderate-to-severe atopic dermatitis had been positive.

Read More »

J&J wins trial in talc product liability lawsuits

A state court jury in Missouri returned a verdict in J&J’s favor in the latest trial arising out of lawsuits alleging its talc-based products can increase ovarian cancer risk.

Read More »

Britain detects bird flu on premises in eastern England

Britain said it had detected bird flu on premises in eastern England during routine checks carried out following the confirmation of the virus at a nearby farm.

Read More »

Current Realities of the Audience Economy, from a Programmatic Perspective

Healthcare marketers have this grand vision of reaching the right patient/caregiver/healthcare professional (HCP) with the right message, at the right time, in the right context.

Read More »

Following Up on Bristol-Myers Squibb’s Restructuring Plans, Company Makes Move to Shift 1,250 Workers Out of Hopewell Township Site

In October, Bristol-Myers Squibb announced a reorganization plan of its research and development group. Part of that restructuring will include the closure of two sites in Hopewell Township by 2020 – a move that could displace up to 1,250 employees.

Read More »

Guselkumab Outperforms Humira In Study

Study data showed patients treated with guselkumab experienced significantly greater improvements compared with the anti-TNF-alpha treatment Humira.

Read More »

Chi-Med Shows Off Phase III Cancer Drug Data

Chi-Med’s fruquintinib met all main endpoints in a Phase III trial as a third-line treatment in patients with locally advanced or metastatic colorectal cancer.

Read More »

Sanofi Pasteur Inks $645 Million RSV Deal With AstraZeneca’s MedImmune

Paris-based Sanofi Pasteur announced that it had inked a development agreement with MedImmune, the research-and-development art of AstraZeneca.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom